Stock Screener App

Frei -

Installieren

1.79

7.01% -0.135

Fate Therapeutics Inc (FATE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView

Fate Therapeutics stock stands 97.96 percent higher year to date - ad-hoc-news.de

Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore

Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance UK

Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com - Investing.com Nigeria

Fate Therapeutics appoints Jamie Harrell to lead commercial strategy - Investing.com

Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com South Africa

Fate Therapeutics appoints Jamie Harrell to lead commercialization - Investing.com

Fate Therapeutics appoints Jamie Harrell to lea... - Pluang

Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com Canada

Fate Therapeutics names Jamie Harrell SVP of commercial operations - StreetInsider

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies - GlobeNewswire Inc.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire

Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan

Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 - MarketBeat

Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock - AD HOC NEWS

Fate Therapeutics stock adds two Q4 conference dates - AD HOC NEWS

Fate Therapeutics stock gained 4.74 percent on October 5 - AD HOC NEWS

Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving AverageTime to Sell? - marketbeat.com

Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Australia

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay - stocktitan.net

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Fate Therapeutics, Inc. (F6T.F) Stock Price, News, Quote & History - Yahoo! Finance Canada

Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire Inc.

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire

FRAUD AND MANIPULATION—S.D. Cal.: Pharma company ducks securities fraud claim for lack of loss causation - VitalLaw.com

Gross profit of Fate Therapeutics, Inc. – HAN:F6T - TradingView

Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial - Yahoo Finance

Fate Therapeutics receives $15m CIRM grant for lupus trial - Investing.com

Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada

Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative

Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative

Fate Therapeutics Announces Receipt of California Institute - GlobeNewswire

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - Yahoo Finance

Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK

Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - Yahoo Finance

A study explores cell therapy without preparatory chemotherapy. Fate will present four at ACR. - stocktitan.net

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com UK

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com South Africa

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada

Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com UK

OLMA

$6.58

4.22%

ZVRA

$9.94

3.21%

SLDB

$5.53

3.66%

AVTX

$11.27

6.16%

NVCT

$18.60

1.74%

WVE

$3.13

1.88%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters